T2DM, CVD) Clinical Development A phase 1 study with healthy or obese subjects is completed NCT06481098 A phase 2 study with obese subjects is currently ongoing in the US NCT07205900 A phase 2 study with subjects with type 2 diabetes mellitus is currently ongoing in the US NCT07527650 Publications Poster Cross-Species Pharmacokinetic Comparison and Human PK Prediction of HM15275, A Novel Long-Acting GLP1/GIP/GLUCAGON Triple Agonist for Treatment of Obesity International Society for the Study of Xenobiotics (ISSX), 2026 Download Poster Efficacy and Safety of HM15275, a Novel Long-Acting Triple Agonist in Adults With Obesity ObesityWeek, 2025 Download Poster Mechanistic insights into the potent anti-obesity effects of HM15275, a novel long-acting GLP-1/GIP/glucagon triple agonist European Association for the Study of Diabetes (EASD), 2025 Download Poster Safety, Tolerability, and Pharmacokinetics of HM15275, a Novel GLP-1, GIP, and Glucagon Triple Receptor Agonist: Preliminary Results from a Phase 1 Study American Diabetes Association (ADA) Scientific Sessions, 2025 Download Poster Robust Anti-obesity Effect and Mechanistic Insights of HM15275, A Novel Long-acting GLP-1/GIP/Glucagon Triple Agonist in Animal Model of Obesity American Diabetes Association (ADA) Scientific Sessions, 2025 Download Poster Metabolic Adaptation of Liver with Treatment of HM15275, A Long-Acting GLP-1/GIP/Glucagon Triple Agonist, Supporting Lean Mass Preservation American Diabetes Association (ADA) Scientific Sessions, 2025 Download Poster Potent weight loss effect and mechanism of a novel long-acting GLP-1/GIP/GCG triple agonist, HM15275, in animal model of obesity ObesityWeek, 2024 Download Poster Therapeutic potential of HM15275, a novel long-acting GLP-1/GIP/GCG triple agonist, in animal models of heart failure American Diabetes Association (ADA) Scientific Sessions, 2024 Download Poster Potent weight loss and favorable glycemic control effects of a novel long-acting GLP-1/GIP/GCG triple agonist, HM15275, in animal models American Diabetes Association (ADA) Scientific Sessions, 2024 Download Poster Potential cardioprotective effects of HM15275, a novel, long-acting GLP-1/GIP/GCG triple agonist, in animal models of hypertension American Diabetes Association (ADA) Scientific Sessions, 2024 Download Poster Nephroprotective effects of a novel long-acting GLP-1/GIP/GCG triple agonist, HM15275, in preclinical models of acute and chronic kidney diseases American Diabetes Association (ADA) Scientific Sessions, 2024 Download
Because if you do so, you significantly reduce the risk of cardiovascular disease
Semaglutide is a synthetic medication engineered to mimic GLP-1's effects while remaining active for approximately 7 days, enabling practical once-weekly dosing
Nasuprot tome, samo 22% uesnika u placebo grupi postiglo je normoglikemiju
Wegovy Compared to Ozempic and Other GLP-1 Agents Although Wegovy and Ozempic both contain semaglutide, Wegovy is specifically formulated and approved for weight loss, whereas Ozempic is indicated for diabetes treatment
Effectiveness of single and combined antioxidant therapy in patients with astheno-necrozoospermia from non-bacterial epididymitis: effects after acetyl-carnitine or carnitine-acetyl-carnitine
